Atracurium besylate

SKU: orb1221923

Description

Atracurium Besilate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Atracurium is classified as an intermediate-duration non-depolarizing neuromuscular-blocking agent.(In Vitro):Atracurium besylate (10 μM; 72 h) promotes astroglial but not neuronal differentiation in HSR040622 and HSR040821 cells.Atracurium besylate (10 μM; 48 h) reduces tumor engraftment and increases survival of mice xenotransplanted with ex-vivo treated GSCs.Atracurium besylate (2.4 μM; 120 min) induces a complete fade of the tetanic contraction while only slightly affected the twitch in rat extensor digitorum longus muscle cells.(In Vivo):Atracurium besylate (1, 5, 10, 20, 50 mg/kg; i.v.) induces bronchoconstriction in DBA/2 and SJL mice.Atracurium besylate (4.8 mg/kg; i.v.) induces neuromuscular blockade in rats.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 64228-81-5
• MW: 1243.49
• Purity: >98% (HPLC)
• Formula: C₆₅H₈₂N₂O₁₈S₂
• SMILES: [O-]S(=O)(=O)c1ccccc1.COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.[O-]S(=O)(=O)c1ccccc1
• Target: nAChR
• Solubility: DMSO : 50 mg/mL 40.21 mM

Bioactivity

• In Vivo:
  Atracurium besylate (1, 5, 10, 20, 50 mg/kg; i. v.) induces bronchoconstriction in DBA/2 and SJL mice. Atracurium besylate (4.8 mg/kg; i. v.) induces neuromuscular blockade in rats. Animal model: 5-12 weeks, 15-20 g male mice. Dosage: 1, 5, 10, 20, 50 mg/kg. Administration: I. v. Result: Induced bronchoconstriction and Atracurium-induced airway hyperresponsiveness in DBA/2 mice was eliminated in a dose-dependent manner by pretreatment with atropine or pancuronium. Animal model: 290 ± 30 g Male Sprague±Dawley rats (60 mg/kg heat-killed Corynebacteriumparvum for i. v.). Dosage: 4.8 mg/kg. Administration: I. v. Result: Induced neuromuscular blockade in Corynebacteriumparvum-injected rats.
  Read more...
• In Vitro:
  Atracurium besylate (10 μM; 72 h) promotes astroglial but not neuronal differentiation in HSR040622 and HSR040821 cells. Atracurium besylate (10 μM; 48 h) reduces tumor engraftment and increases survival of mice xenotransplanted with ex-vivo treated GSCs. Atracurium besylate (2.4 μM; 120 min) induces a complete fade of the tetanic contraction while only slightly affected the twitch in rat extensor digitorum longus muscle cells. Cell Proliferation Assay Cell line: glioblastoma stem (GSC) cells. Concentration: 3, 10, 20 μM. Incubation time: 72 h. Result: Increased the percentage of GFP-positive cells in a dose-dependent manner from 5.3% in DMSO to 15.4%, 81.1%, and 86.8% in 3 μM, 10 μM, and 20 μM, respectively.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Atracurium Besylate | Atracurium Dibesylate

Quick Database Links

Gene Symbol

nAChR